BGPT: Paper Review: Alveolar and intraparenchymal proteasome in sarcoidosis

Explore by Goal

Quick Explanation Copied

Paper reviewed: “Alveolar and intraparenchymal proteasome in sarcoidosis” (Respiratory Medicine, 19 Sep 2014; DOI: 10.1016/j.rmed.2014.09.004).

Most supported claim (from provided full text): Higher extracellular alveolar total proteasome concentration associates with clinical “active” sarcoidosis (especially stages II–III).

Long Explanation

Paper Review (visual + skeptical, evidence-based)

“Alveolar and intraparenchymal proteasome in sarcoidosis” • Respiratory Medicine • 19 Sep 2014 • DOI: 10.1016/j.rmed.2014.09.004

1) What the paper measured (so we know what “changed”)

BAL supernatant: total proteasome concentration (ELISA) and proteasome-like hydrolytic activity on fluorogenic substrates; activity was inhibited by epoxomicin (a proteasome inhibitor used to attribute substrate hydrolysis to proteasomes).
Immunoproteasome in lung tissue: immunohistochemistry for immunoproteasome proteins; strongest staining reported in type II pneumocytes and granulomas; weaker/occasional staining in controls.
BAL alveolar macrophages: immunocytochemistry scoring for LMP2/LMP7/20S proteasome subunits; no significant group differences reported for macrophage positivity/scores.

2) Study design at a glance

Population: 67 adult sarcoidosis patients (36M/31F; mean age 50 ± 14.5) vs 18 non-smoking healthy controls (8M/10F; mean age 48 ± 15).

Activity classification: “Active” based on preceding 3 months of clinical worsening and/or lung function change and/or radiographic progression; no corticosteroids reported for those with worsening (per the paper’s description).

Key output types: extracellular proteasome concentration/activity (BAL) + tissue immunoproteasome distribution (IHC) + macrophage marker scoring (ICC).

3) Visualizing the core quantitative result (BAL proteasome concentration)

Evidence for the group difference: Active sarcoidosis shows significantly higher total proteasome concentration than inactive sarcoidosis and healthy controls.

4) Stage dependence: active stage II & III appear elevated

Reported significance: active stage II and stage III are significantly greater than the respective inactive stage comparisons.

5) Functional attribution: proteasome activity is epoxomicin-sensitive

The paper reports that proteasome-specific fluorogenic substrate hydrolysis occurs in BAL supernatant and is markedly inhibited by epoxomicin (p<0.001), supporting that the measured hydrolysis is proteasome-dependent.

Critical nuance: While epoxomicin inhibition supports proteasome-specific hydrolysis, the paper reports no significant differences among the three specific “protein-related” proteasomal activities between active vs inactive stages or vs controls.

6) BAL macrophage immunoproteasome: no significant group differences

Table 3 in the provided full text reports BAL macrophage positivity percentages and semiquantitative “AM scores” for LMP2/LMP7/20S, with non-significant p-values for sarcoidosis vs controls.

Interpretation restraint: “No difference in macrophage positivity” does not mean “macrophages are irrelevant”; it means the immunocytochemical readouts used here did not separate groups in this dataset.

7) Mechanistic story the authors propose (and what is solid vs inferred)

Authors’ core inference: granulomatous lung structures (epithelioid cells/giant cells) show strong immunoproteasome staining, potentially aligning with increased extracellular proteasome in BAL during active disease.

What is directly supported by data in the provided text:

Active sarcoidosis shows higher BAL total proteasome concentration than inactive and controls.
Immunoproteasome proteins are strongly detected in specific lung cell populations in sarcoidosis tissue (type II pneumocytes and granuloma epithelioid/giant cells).
BAL macrophage positivity/scores for LMP2/LMP7/20S do not differ significantly between sarcoidosis and controls.
Epoxomicin inhibits the measured BAL fluorogenic hydrolysis consistent with proteasome-dependent activity readouts.

What is inferred / not yet proven (key unknowns):

Transport mechanism: the authors explicitly note that the mechanisms for proteasome transport into the alveolar lumen were not addressed.
Cause vs association: “Active disease” is clinically defined; the study does not demonstrate that increased extracellular proteasome is causally upstream of disease activity (it could be a consequence of inflammation/tissue damage). The paper attempts to argue against major alveolar cell lysis using LDH correlation, but this is still correlational.
Immunoproteasome vs total proteasome quantification: ELISA for “total proteasome” does not quantitatively distinguish 20S from immunoproteasome; immunohistochemistry suggests immunoproteasome-rich sources in tissue, but the BAL concentration assay is not immunoproteasome-specific.

8) Skeptical critique: what could confound or limit interpretation?

Inactive vs residual disease activity: A limitation acknowledged by the authors is that they did not perform PET or additional biomarker investigations to exclude residual activity in patients classified as inactive. That can dilute or misclassify the “activity dependence” signal.
Proteasome measurement granularity: The BAL ELISA provides total proteasome concentration; it does not separate immunoproteasome from other proteasome forms. Hence, the measured “total” could be influenced by multiple sources/complexes not specifically immunoproteasome.
Small tissue ICC subset: Immunocytochemistry of BAL macrophages was performed on a subset (11 sarcoidosis patients and 7 controls), so confidence in “no difference in macrophages” depends on that sample size and the reproducibility of scoring.
Activity definition bias: “Active” disease is a composite clinical-radiographic-functional construct; unmeasured co-variables (e.g., differences in other inflammatory processes at sampling time) could drive extracellular proteasome. The paper does not report extensive adjustment models in the provided text.
Therapeutic inference is speculative: The conclusion suggests proteasome inhibitors “might” be considered if confirmed, but the study does not test inhibitors in sarcoidosis. Treat it as hypothesis generation, not evidence for efficacy.

What would disprove/seriously change the main conclusion?

Demonstrating that extracellular BAL proteasome concentration does not track independent measures of active granulomatous inflammation when residual activity is rigorously excluded (e.g., via PET/biomarkers as the authors note).
Showing that the signal is driven by non-specific protein release and correlates strongly with additional lysis/damage markers beyond LDH (or is absent after controlling for those markers).

9) Quick “paper map” (what connects to what)

Important: This is not causality; it’s a mapping of what the paper reports being higher/more abundant vs not different.

Author reviews to explore next

Feedback:

Updated: April 08, 2026